NEUP — Neuphoria Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $18.61m
- -$1.22m
- $1.17m
Annual cashflow statement for Neuphoria Therapeutics, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | — | -21.4 | -15.5 | -0.37 | -13.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | — | 1.5 | -1.31 | 0.148 | 4.49 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -15.8 | 4.72 | 1.59 | 0.105 | -3.92 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -15.8 | -14.6 | -14.7 | 0.077 | -12.4 |
| Capital Expenditures | -0.001 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.452 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.451 | — | — | — | — |
| Financing Cash Flow Items | -4.15 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.6 | 3.86 | 15.1 | 1.53 | 17.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.67 | -11 | 0.505 | 1.6 | 5.58 |